Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200323184> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3200323184 abstract "Abstract Purpose Patients with Oligometastatic (OM) non-small-cell lung cancer (NSCLC) (≤ 3 metastases) might benefit from radical ablative treatment of both primary tumor and metastases. However, the role of ablative therapy in OM patients with locally advance primary tumor has not been evaluated. The aim of our study was to analyze the efficacy and safety of ablative treatment in patients with unresectable primary tumor and synchronous Oligometastases, in terms of response rate, progression free survival (PFS) and overall survival (OS). Methods/Patients Retrospective study of patients with Oligometastatic NSCLC (≤ 3 lesions in a unique location) and unresectable primary tumor, treated with radical intent (chemo-radiotherapy for primary tumor and surgery, radiotherapy, Stereotactic Body Radiation Therapy (SBRT) or radiofrequency for all known metastases) between October 2011 and March 2015. Results Thirty patients met inclusion criteria. Median age was 58 years, 76.6% were male, and 96.6% had ECOG 0-1. Histology: Adenocarcinoma (63.6%), squamous carcinoma (20%), and other histology (13.4%). All patients had unresectable primary tumor and/or mediastinal lymph nodes. Site of metastases: brain (46.6%), lung (23.3%), bone (20%), other locations (9.9%). Sequential thoracic radiotherapy (40%) and concomitant radiotherapy (60%). Treatment of metastases: SBRT (53.3%), external radiotherapy (26.6%), surgery (13.6%), radiofrequency (3.3%), none (3.3%). Toxicity grade 3 (29.4%). Response rate was 69.9%, median PFS 11.1 months (IC 95%: 8.2-13.7), and median OS 20.2 months (IC: 15.6-20.3). Conclusions Radical treatment for oligometastatic and unresectable NSCLC patients is a safe therapeutic strategy and it could be contemplated as an effective therapeutic alternative in selected patients." @default.
- W3200323184 created "2021-09-27" @default.
- W3200323184 creator A5001593889 @default.
- W3200323184 creator A5015419018 @default.
- W3200323184 creator A5028531765 @default.
- W3200323184 creator A5033145068 @default.
- W3200323184 creator A5039076668 @default.
- W3200323184 creator A5053968478 @default.
- W3200323184 creator A5064135253 @default.
- W3200323184 creator A5091790692 @default.
- W3200323184 date "2019-12-31" @default.
- W3200323184 modified "2023-09-30" @default.
- W3200323184 title "Prognostic Impact of Ablative Therapy in Oligometastatic Non-Small-Cell Lung Cancer (NSCLC) with Unresectable Primary Tumor" @default.
- W3200323184 doi "https://doi.org/10.36959/825/583" @default.
- W3200323184 hasPublicationYear "2019" @default.
- W3200323184 type Work @default.
- W3200323184 sameAs 3200323184 @default.
- W3200323184 citedByCount "0" @default.
- W3200323184 crossrefType "journal-article" @default.
- W3200323184 hasAuthorship W3200323184A5001593889 @default.
- W3200323184 hasAuthorship W3200323184A5015419018 @default.
- W3200323184 hasAuthorship W3200323184A5028531765 @default.
- W3200323184 hasAuthorship W3200323184A5033145068 @default.
- W3200323184 hasAuthorship W3200323184A5039076668 @default.
- W3200323184 hasAuthorship W3200323184A5053968478 @default.
- W3200323184 hasAuthorship W3200323184A5064135253 @default.
- W3200323184 hasAuthorship W3200323184A5091790692 @default.
- W3200323184 hasBestOaLocation W32003231841 @default.
- W3200323184 hasConcept C121608353 @default.
- W3200323184 hasConcept C126322002 @default.
- W3200323184 hasConcept C126838900 @default.
- W3200323184 hasConcept C143998085 @default.
- W3200323184 hasConcept C19617505 @default.
- W3200323184 hasConcept C2776256026 @default.
- W3200323184 hasConcept C2779013556 @default.
- W3200323184 hasConcept C2779177807 @default.
- W3200323184 hasConcept C2779384505 @default.
- W3200323184 hasConcept C2780283643 @default.
- W3200323184 hasConcept C2781182431 @default.
- W3200323184 hasConcept C509974204 @default.
- W3200323184 hasConcept C71924100 @default.
- W3200323184 hasConcept C81729549 @default.
- W3200323184 hasConceptScore W3200323184C121608353 @default.
- W3200323184 hasConceptScore W3200323184C126322002 @default.
- W3200323184 hasConceptScore W3200323184C126838900 @default.
- W3200323184 hasConceptScore W3200323184C143998085 @default.
- W3200323184 hasConceptScore W3200323184C19617505 @default.
- W3200323184 hasConceptScore W3200323184C2776256026 @default.
- W3200323184 hasConceptScore W3200323184C2779013556 @default.
- W3200323184 hasConceptScore W3200323184C2779177807 @default.
- W3200323184 hasConceptScore W3200323184C2779384505 @default.
- W3200323184 hasConceptScore W3200323184C2780283643 @default.
- W3200323184 hasConceptScore W3200323184C2781182431 @default.
- W3200323184 hasConceptScore W3200323184C509974204 @default.
- W3200323184 hasConceptScore W3200323184C71924100 @default.
- W3200323184 hasConceptScore W3200323184C81729549 @default.
- W3200323184 hasIssue "1" @default.
- W3200323184 hasLocation W32003231841 @default.
- W3200323184 hasOpenAccess W3200323184 @default.
- W3200323184 hasPrimaryLocation W32003231841 @default.
- W3200323184 hasRelatedWork W2082912800 @default.
- W3200323184 hasRelatedWork W2366100192 @default.
- W3200323184 hasRelatedWork W2395953112 @default.
- W3200323184 hasRelatedWork W2403361534 @default.
- W3200323184 hasRelatedWork W2908922480 @default.
- W3200323184 hasRelatedWork W3171615116 @default.
- W3200323184 hasRelatedWork W4200188553 @default.
- W3200323184 hasRelatedWork W4252107748 @default.
- W3200323184 hasRelatedWork W1899415052 @default.
- W3200323184 hasRelatedWork W1912371934 @default.
- W3200323184 hasVolume "3" @default.
- W3200323184 isParatext "false" @default.
- W3200323184 isRetracted "false" @default.
- W3200323184 magId "3200323184" @default.
- W3200323184 workType "article" @default.